Huawei has unveiled the Sense G1, its first continuous glucose monitoring (CGM) device. The separate sensor is worn on the arm and continuously tracks glucose, transmitting readings to a connected phone or smartwatch. Huawei’s teaser also confirms alerts for abnormal readings, but it does not yet provide a full specification sheet, price or sales schedule.
Sense G1 is not a smartwatch software feature. Some Huawei watches, including Watch 4 and Watch GT models, can estimate the risk of elevated glucose levels from physiological data, but they do not directly measure glucose. Sense G1 instead uses a dedicated sensor designed to feed glucose data into Huawei’s wider phone and wearable ecosystem.
Like other CGM systems, Sense G1 does not read glucose directly from blood. A sensor placed beneath the skin measures glucose in interstitial fluid, the fluid between cells, and wirelessly relays the reading and its upward or downward trend to the paired device. Such readings can lag behind finger-prick blood glucose measurements, particularly after meals, during exercise or when levels are changing quickly.
Huawei is reported to have obtained Class III medical-device certification for Sense G1 in China, the highest category in the country’s local system. That certification does not automatically extend to other markets: Huawei has not announced CE marking, European reimbursement arrangements, full app compatibility or a European launch date. The remaining regulatory and availability details will determine how broadly the device can compete in the established CGM market.
